Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

I also find the spleen lesion disappeared in one ovarian patient at medium dosage hard to believe. But it actually happened.

What you find hard to believe and what actually happens in clinical trials are two different things.

Clinical data are aligning well with pre-clinical data. I understand the pre-clinical data so I’m confident with my prediction.

6% tumor reduction is still well away from a partial response (30% tumor shrinkage) which you are claiming will happen by upping the dose.

The 750 mg/m2 cohort is still ongoing. So there’s no PR yet. If management doesn’t think 750 will probably have a greater benefit, why not just stop at 450 and call that the MTD?

So by your assertion the guy in the 11th cohort at 750mg/m2 who is 3 months into treatment should at least have partial response by now. Where's the PR for that?